Biogen
FDA Approves Controversial Alzheimer's Drug
Jul 12, 2021 at 03:30 pm by Staff
On June 7, the Food & Drug Administration approved Aduhelm (aducanumab) to treat Alzheimer's patients, making it the first new drug approval for a disease impacting more t.... Read More
Expanding ADNI: Alzheimer's Biomarker Study Embarks on Next Phase
Oct 11, 2016 at 02:55 pm by Staff
The landmark Alzheimer's Disease Neuroimaging Initiative (ADNI) began in October 2004 with a goal of finding more sensitive and accurate methods to detect Alzheimer's disease.... Read More
Biogen Investigational Drug Shows Early Promise
Oct 11, 2016 at 02:55 pm by Staff
Boston-based biotech company Biogen had pre-clinical research and Phase 1b results for aducanumab, its investigational antibody treatment for early Alzheimer's disease, publis.... Read More